Patrice Rioux
Fundador en THIOGENESIS THERAPEUTICS, CORP. .
Fortuna: 3 M $ al 31/05/2024
Relaciones activas
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Kim Tsuchimoto | F | 61 | 9 años | |
| Christopher Starr | M | 71 | 10 años | |
| Brook Riggins | M | 58 | - | |
| Chandler Robinson | M | 40 | 10 años | |
| Vincent P. Stanton | M | - |
Thiogenesis Therapeutics, Inc.
 Thiogenesis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thiogenesis Therapeutics, Inc. engages in the development of novel compounds that are based on thiols, thiol derivatives or S-H groups. The company was founded by Patrice P. Rioux and Vincent P. Stanton and is headquartered in Belmont, MA. | - |
| Michael Brown | M | 67 | 10 años | |
| Arthur Klausner | M | 64 | 7 años | |
| Raymond Anderson | M | 82 | 7 años | |
| W. Mullally | M | 50 | 6 años | |
| Andrew Cittadine | M | 52 | 3 años | |
| Laura Kelly | F | - | 3 años |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
| Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
|---|---|---|---|---|
| Georgia Erbez | F | 57 |
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 2 años |
| Julie Smith | F | 53 |
Raptor Pharmaceuticals, Inc.
 Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 4 años |
| Andrew Mazar | M | 62 | 8 años | |
| Todd C. Zankel | M | 60 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 3 años |
| Timothy Walbert | M | 57 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 4 años |
| Marc Patrick Reichenberger | M | 59 |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | - |
| Suzanne Bruhn | M | 60 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 5 años |
| Vijay Samant | M | 77 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 3 años |
| Craig Johnson | M | 62 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | 1 años |
| Karl Cahill | M | 51 |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | - |
| Justin Ford | M | - |
Raptor Pharmaceuticals, Inc.
Raptor Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Raptor Pharmaceuticals, Inc. operates as a biopharmaceutical company which develops and markets life-altering therapeutics. The company is headquartered in Novato, CA. | 3 años |
| Octávio Costa | M | - | - |
Estadísticas
| País | Relaciones | % del total |
|---|---|---|
| Estados Unidos | 21 | 91.30% |
| Canadá | 4 | 17.39% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Patrice Rioux
- Red Personal
